New drug BL-M14D1 targets tough cancers in early human trial
NCT ID NCT07080242
First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times
Summary
This early-stage trial is testing a new drug called BL-M14D1 in about 120 people with advanced small cell lung cancer or other neuroendocrine cancers that have spread or cannot be removed. The drug works by homing in on a protein called DLL3 found on these cancer cells and delivering a chemotherapy agent directly to them. The main goals are to check the drug's safety and find the right dose, while also looking for early signs that it might shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BL-M14D1 (a drug that targets a protein called DLL3 on cancer cells and delivers a chemotherapy payload)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced small cell lung cancer or other neuroendocrine cancers that have stopped responding to standard therapy.
- What could go wrong
- This is a very early Phase 1 trial with only 120 participants, so the drug may turn out to be unsafe or not effective. Side effects from the chemotherapy payload could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clearview Cancer Institute
NOT_YET_RECRUITINGHuntsville, Alabama, 35805, United States
-
Emory Winship
RECRUITINGAtlanta, Georgia, 30322, United States
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
-
John Theurer Cancer Center-Hackensack
RECRUITINGHackensack, New Jersey, 07601, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
NEXT Dallas
RECRUITINGDallas, Texas, 75039, United States
-
NEXT Houston
RECRUITINGHouston, Texas, 77054, United States
-
NEXT Oncology Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
Ohio State University
RECRUITINGColumbus, Ohio, 43201, United States
-
Prisma Health Cancer Institute
RECRUITINGGreenville, South Carolina, 29605, United States
-
Providence Cancer Institute
RECRUITINGPortland, Oregon, 97213, United States
-
Rutgers Cancer Institute
RECRUITINGNew Brunswick, New Jersey, 08901, United States
-
START Dallas- Fort Worth
RECRUITINGDallas, Texas, 76104, United States
-
START- San Antonio
RECRUITINGSan Antonio, Texas, 78229, United States
-
UCLA
NOT_YET_RECRUITINGLos Angeles, California, 90095, United States
-
UCSF- San Francisco (Helen Diller Family Comprehensive Cancer Center)
NOT_YET_RECRUITINGSan Francisco, California, 94158, United States
-
University of Colorado - Anschutz Cancer Pavilion
RECRUITINGAurora, Colorado, 80045, United States
-
University of Washington/Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98195, United States
-
Valkyrie Clinical Trials
RECRUITINGLos Angeles, California, 90067, United States
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06520-8028, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can donor immune cells boost lung cancer remission?